Wells Fargo & Company Reiterates “Equal Weight” Rating for Affimed (NASDAQ:AFMD)

Wells Fargo & Company restated their equal weight rating on shares of Affimed (NASDAQ:AFMD) in a research note released on Tuesday,Benzinga reports. Wells Fargo & Company currently has a $0.10 target price on the biopharmaceutical company’s stock, down from their prior target price of $11.00.

AFMD has been the subject of a number of other research reports. StockNews.com initiated coverage on shares of Affimed in a report on Sunday. They set a “sell” rating for the company. Leerink Partners reaffirmed a “market perform” rating and set a $0.39 price target (down previously from $5.00) on shares of Affimed in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Affimed presently has an average rating of “Hold” and an average price target of $7.90.

Affimed Stock Down 80.7%

NASDAQ:AFMD opened at $0.13 on Tuesday. Affimed has a twelve month low of $0.13 and a twelve month high of $8.95. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The stock has a fifty day simple moving average of $0.78 and a 200-day simple moving average of $1.47.

Institutional Investors Weigh In On Affimed

Several large investors have recently modified their holdings of AFMD. Jane Street Group LLC bought a new position in shares of Affimed during the third quarter valued at approximately $44,000. Intellectus Partners LLC lifted its holdings in Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 32,053 shares during the period. Finally, Northern Trust Corp bought a new stake in Affimed during the 4th quarter valued at $218,000. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.